Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study.
biomarkers, tumor
immunotherapy
lung neoplasms
tumor biomarkers
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
accepted:
21
06
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
21
9
2021
Statut:
ppublish
Résumé
Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography-computed tomography ( Maximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors. Associations between these parameters and overall survival (OS) were evaluated as well as their accuracy to predict early treatment discontinuation (ETD). A high MTV and a high TLG were significantly associated with a lower OS (p<0.001). The median OS in patients with MTV above the median (36.5 cm MTV is a strong prognostic and predictive factor in patients with NSCLC treated with PD1 inhibitors and can be easily determined from routine
Sections du résumé
BACKGROUND
Reliable predictive and prognostic markers are still lacking for patients treated with programmed death receptor 1 (PD1) inhibitors for non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the prognostic and predictive values of different baseline metabolic parameters, including metabolic tumor volume (MTV), from 18F-fluorodeoxyglucose positron emission tomography-computed tomography (
METHODS
Maximum and peak standardized uptake values, MTV and total lesion glycolysis (TLG), as well as clinical and biological parameters, were recorded in 75 prospectively included patients with NSCLC treated with PD1 inhibitors. Associations between these parameters and overall survival (OS) were evaluated as well as their accuracy to predict early treatment discontinuation (ETD).
RESULTS
A high MTV and a high TLG were significantly associated with a lower OS (p<0.001). The median OS in patients with MTV above the median (36.5 cm
CONCLUSION
MTV is a strong prognostic and predictive factor in patients with NSCLC treated with PD1 inhibitors and can be easily determined from routine
Identifiants
pubmed: 32709713
pii: jitc-2020-000645
doi: 10.1136/jitc-2020-000645
pmc: PMC7380842
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MI reports personal fees from AstraZeneca, Bristol-Myers Squibb, Roche, Boehringer-Ingelheim, and Merck & Co outside the submitted work.
Références
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):241-51
pubmed: 25193652
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Crit Rev Oncol Hematol. 2018 Sep;129:27-39
pubmed: 30097235
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Nucl Med. 2009 May;50 Suppl 1:11S-20S
pubmed: 19380405
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Thorac Oncol. 2020 Apr;15(4):499-519
pubmed: 31870882
Expert Opin Biol Ther. 2017 Mar;17(3):305-312
pubmed: 28064556
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
PLoS One. 2015 Oct 16;10(10):e0140830
pubmed: 26473950
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1898-906
pubmed: 24852188
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):930-939
pubmed: 30488098
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167
pubmed: 31760467
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nucl Med Commun. 2019 Aug;40(8):802-807
pubmed: 31045745
Anticancer Res. 2019 Feb;39(2):815-825
pubmed: 30711962
J Immunother Cancer. 2019 Dec 4;7(1):341
pubmed: 31801636
Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43
pubmed: 24811577
J Clin Med. 2020 Mar 07;9(3):
pubmed: 32156047
Clin Cancer Res. 2018 Dec 1;24(23):6098
pubmed: 30510087
Lung Cancer. 2016 Apr;94:81-7
pubmed: 26973211
J Immunother Cancer. 2018 Nov 23;6(1):128
pubmed: 30470252
J Nucl Med. 2020 Jun;61(6):821-826
pubmed: 31862803
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Clin Nucl Med. 2018 Jan;43(1):e8-e17
pubmed: 29112011
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200
pubmed: 19915839
JAMA Oncol. 2018 Nov 1;4(11):1543-1552
pubmed: 30193240